

## **PRESS RELEASE**

### **James S. MacDonald joins HμREL® Corporation Board**

Beverly Hills CA (April 13, 2009)

James S. MacDonald, Ph.D. has joined HμREL Corporation's Board of Directors<sup>1</sup>.

During a pharmaceutical development career that has spanned more than three decades, Dr. MacDonald has brought hundreds of new molecular entities forward from discovery into development, over thirty of which have become globally registered, major drugs, including Vasotec®, Zocor®, Primaxin®, Clinoril®, Pepcid®, Fosamax®, Clarinex®, Nasonex®, and Vitorin®, among others. Until his retirement at the end of 2008, he was Executive Vice President of Preclinical Development for Schering-Plough Research Institute (SPRI), the pharmaceutical development arm of Schering Corporation. He joined SPRI in 1994 as Senior Vice President, Drug Safety and Metabolism, having been recruited by SPRI's then-head Dr. Cecil Pickett. Over the next 14 years Dr. MacDonald played a leading role in building one of the most capable drug discovery and development organizations in the world. In addition to his line responsibility for Drug Safety and Metabolism, as co-chairman of SPRI's Early Development Committee he directed the activities surrounding the movement of drug candidates from discovery research into and through the development process. From 1977 until 1994, Dr. MacDonald held positions of increasing responsibility at Merck, including Executive Director of Toxicology. He received his Ph.D. in toxicology in 1975 from the University of Cincinnati and joined Merck after completing a post-doctoral fellowship at Vanderbilt University. He became a diplomate of the American Board of Toxicology in 1980.

"HμREL is honored to have the benefit of Jim MacDonald's commitment and his extraordinary experience," said Robert Freedman, HμREL's Chairman and CEO. "Jim will provide deeply informed counsel as we identify and implement the applications where HμREL's capabilities can make the biggest impact. Jim's effectiveness will be felt nowhere more than in drug safety—an area of particular expertise for him and an area where we expect HμREL ultimately to add great value. We welcome Jim as a colleague."

HμREL Corporation is the world leader in developing microfluidic, multi-tissue cell cultures and assay platforms which provide in vitro alternatives to animal testing while offering improved human-relevance of prediction to scientists in the pharmaceutical, biotech, cosmetics, consumer products and industrial products industries.

Contact: Ruth Lundi, Administrator  
HμREL Corporation  
8840 Wilshire Blvd., 2<sup>nd</sup> Floor, Beverly Hills, CA 90211  
(310) 652-5900  
rlundi@hurelcorp.com  
www.hurelcorp.com

---

<sup>1</sup> Effective upon the closing of HμREL's Series "A" financing. Until such time, Dr. MacDonald serves as HμREL's Senior Adviser.